DEVELOPING DRUG PRODUCTS IN AN AGING SOCIETY. FROM CONCEPT TO PRESCRIBING

1. Healthcare Provisions in an Aging Society: U.S. Perspective
2. Healthcare Provision in an Aging Society—The European Perspective
3. Healthcare Provisions in the Aging Society: Japanese Perspectives
4. Old, Very Old and Frail
5. Age and the Process of Aging
6. Comprehensive Geriatric Assessment
7. Patients’ Clinical Characteristics, Disease Experience, and Perception
8. Ethical Considerations in Performing Clinical Trials in and for Older People
9. Patient Reported Outcomes in Clinical Trials and Practice with Older Patients
10. Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population
11. The Expectation to Treatment Model: A Framework for Adherence and Effectiveness
12. Pharmacoepidemiology and Pharmacovigilance for Safety and Efficacy in Older People
13. Defining Patient Centric Drug Product Design and Its Impact on Improving Safety and Effectiveness
14. Dosing Considerations in Older Adults
15. Oral Drug Product Use in the Elderly Patient Population
16. Drug Product Development for Older Adults—Multiparticulate Formulations
17. Considerations for Topical and Transdermal Drug Delivery in Older Adults
18. Parenteral Drug Delivery for Older Patients
19. Inhalation and Nasal Formulations
20. Ophthalmic Drug Development and the Elderly
21. Developing Drug Administration Devices for Geriatric Use
22. Manufacturing Platforms for Patient-Centric Drug Products
23. Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products
24. Prescribing to Older Adults
25. Multimorbidity and Polypharmacy
26. Vaccination in Older Adults
27. Medication Reviews in Older Adults
28. The Personalization of Drug Therapy for Elderly Patients
29. Importance of Clinical Nutrition in Therapy to Older Adults
30. Managing Drug Therapy of Older Patients in Primary and Secondary Care
31. Medication Adherence and Monitoring
32. Medication Compounding in the Provision of Drug Therapy
33. Geriatric Pharmacotherapy: Optimisation Through Integrated Approach in the Hospital Setting
34. European Medicines Agency (EMA): Regulatory Perspectives on Geriatric Medicines
35. Views on the Therapeutic Needs of Older Adults
36. Future Perspectives in Drug Therapy of Older Adults
37. Opportunities in Drug Product Development in an Aging Population

This book aims to address the major aspects of future drug product development and therapy for older adults, giving practical guidance for the rational product and clinical development and prescribing of drug products to this ever growing segment of the population. With authors coming from key “aging” markets such as Europe, the USA, China and Japan, the book will provide valuable information for students, scientists, regulators, practitioners, and other healthcare professionals from academia, industry and regulatory bodies.

Features
• Focuses on drug product development and prescribing for older patients from a multidisciplinary and global perspective
• Provides practical guidelines for developing drugs for this population
• Discusses regulatory pathways for medicines for older patients

Author
Sven Stegemann is the endowed professor for Patient-Centric Drug Product Design and Manufacturing at the Graz University of Technology and Director of Pharmaceutical Business Development at Capsugel. He is scientist, professor and advocate for multidisciplinary research on patient-centric drug products and affordable medicines. Prof. Stegemann trains the next generation of pharmaceutical scientists. His professional experience spans all stages of drug development and manufacturing--from early development through commercial manufacturing.His passion and research led him to found the Geriatric Medicine Society e.V. in 2009, a multidisciplinary network that aims to facilitate the development of age-appropriate medicines that older patients can easily and safely take. He also serves in various organizations as chairman or committee member to progress pharmaceutical sciences.He has established a focus group on patient-centric drug development through the American Association of Pharmaceutical Scientists (AAPS).As This is integral to improving the quality of life of patients in the future.He has spoken at innumerable conferences around the world on patient-centric drug delivery, pharmaceutical product development for special patient populations, multiparticulate technologies, adherence, geriatric drug delivery, quality by design and added value generics.